Dr D'Abreo on the Evolution of ADC Use in the HER2+ Breast Cancer Treatment Landscape

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

Related Keywords

Nina Dabreo ,Perlmutter Cancer Center ,York University Grossman School Of Medicine ,Department Of Medicine ,Division Of Hematology ,Ninad Abreo ,New York University Grossman School ,Medical Oncology ,Nyu Langone X27s Perlmutter Cancer Center ,Onclive Tv ,Neoadjuvant Her2 ,